Webinar
Derk Arts (Castor) and Dr. Bassil Akra (AKRA TEAM) share 60 minutes on EU MDR evidence strategy, AI-assisted chart review, and when US real-world data can support European submissions.
EU MDR post-market clinical follow-up requirements continue to influence device portfolio economics. For some teams, PMCF evidence costs now rival the commercial return on keeping a product in market.
Castor CEO Derk Arts and Dr. Bassil Akra, EU MDR Expert and CEO of AKRA TEAM, work through the questions that rarely get straight answers: what AI-assisted chart review can realistically deliver for evidence generation, when US real-world data can support EU submissions, and how to estimate PMCF costs before committing to a study design.
Leave with a 5-step framework for integrating AI into PMCF strategy. Register free.
Discover all the features offered by Castor EDC
Discover Now